Defining a role for laquinimod in multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 7, Issue 4, 2014, Pages 195-205

  Kieseier, Bernd C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

laquinimod; multiple sclerosis; neuroprotection; relapsing remitting multiple sclerosis

Indexed keywords

LAQUINIMOD;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE SYSTEM; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; T LYMPHOCYTE;

EID: 84903999131     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285614529615     Document Type: Review

References (26)

1. Björk P. Björk A. Vogl T. Stenström M. Liberg D. Olsson A. et al. (2009) Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 7: e97.
2. Brück W. Pförtner R. Pham T. Zhang J. Hayardeny L. Piryatinsky V. et al. (2012) Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol 124: 411–424.
3. Brück W. Wegner C. (2011) Insight into the mechanism of laquinimod action. J Neurol Sci 306: 173–179.
4. Brunmark C. Runström A. Ohlsson L. Sparre B. Brodin T. Aström M. et al. (2002) The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 130: 163–172.
5. Comi G. Abramsky O. Arbizu T. Boyko A. Gold R. Havrdová E. et al. (2010) Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler 16: 1360–1366.
6. Comi G. Jeffery D. Kappos L. Montalban X. Boyko A. Rocca M. et al.; ALLEGRO Study Group (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366: 1000–1009.
7. Comi G. Pulizzi A. Rovaris M. Abramsky O. Arbizu T. Boiko A. et al ; LAQ/5062 Study Group (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371: 2085–2092.
8. Confavreux C. Vukusic S. (2006) Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg 108: 327–332.
9. Fernandez O. (2011) Oral laquinimod treatment in multiple sclerosis. Neurologia 26: 111–117.
10. Filippi M. Rocca M. (2005) MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J Neurol 252(Suppl. 5): v16–v24.
11. Filippi M. Rocca M.A. de Stefano N. (2012) Evidence for a neuroprotective effect of oral laquinimod in relapsing-remitting multiple sclerosis. Poster presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); Lyon, France; 10–13 October.
12. Gold R. Kappos L. Arnold D. Bar-Or A. Giovannoni G. Selmaj K. et al.; DEFINE study investigators (2013) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367: 1098–1107.
13. Hemmati F. Dargahi L. Nasoohi S. Omidbakhsh R. Mohamed Z. Chik Z. et al. (2013) Neurorestorative effect of FTY 720 in a rat model of Alzheimer's disease: comparison with memantine. Behav Brain Res 252: 415–421.
14. Jolivel V. Luessi F. Masri J. Kraus S. Hubo M. Poisa-Beiro L. et al. (2013) Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 136: 1048–1066.
15. Loma I. Heyman R. (2011) Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 9: 409–416.
16. Mishra M. Wang J. Silva C. Mack M. Yong V. (2012) Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am J Pathol 181: 642–651.
17. Oh J. O'Connor P. (2013) Teriflunomide for the treatment of multiple sclerosis. Semin Neurol 33: 45–55.
18. Polman C. Barkhof F. Sandberg-Wollheim M. Linde A. Nordle O. Nederman T. (2005) Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64: 987–991.
19. Ruffini F. Rossi S. Bergamaschi A. Brambilla E. Finardi A. Motta C. et al. (2013) Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult Scler 19: 1084–1094.
20. Schulze-Topphoff U. Shetty A. Varrin-Doyer M. Molnarfi N. Sagan S. Sobel R. et al. (2012) Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PloS ONE 7: 1–9.
21. Thöne J. Ellrichmann G. Seubert S. Peruga I. Lee D. Conrad R. et al. (2012) Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 180: 267–274.
22. Thöne J. Gold R. (2011) Laquinimod: a promising oral medication for the treatment of relapsing–remitting multiple sclerosis. Expert Opin Drug Metab Toxicol 7: 365–370.
23. Toubi E. Nussbaum S. Staun-Ram E. Snir A. Melamed D. Hayardeny L. et al. (2012) Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J Neuroimmunol 251: 45–54.
24. Vollmer T. Sorensen P. Arnold D. ; on behalf of the BRAVO Study Group (2011) A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis [abstract 148]. Presented at Fifth Joint Triennial Congress of the European and Americas Committee for Treatment and Research in Multiple Sclerosis; Amsterdam, Netherlands; October 19–22, 2011. Mult Scler 17: S507.
25. Vollmer T. Sorensen P. Selmaj K. Zipp F. Havrdova E. Cohen J. et al ; on behalf of the BRAVO Study Group (2014) A randomized, placebo-controlled, phase III trial of oral laquinimod for multiple sclerosis. J Neurol 18 February (epub ahead of print).
26. Wegner C. Stadelmann C. Pförtner R. Raymond E. Feigelson S. Alon R. et al. (2010) Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 227: 133–143.